Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

• Autoři: VAN EIMEREN T.; ANTONINI A.; BERG D.; BOHNEN N.; CERAVOLO R.; DRZEZGA A.; HÖGLINGER G.; HIGUCHI M.; LEHERICY S.; LEWIS S.; MONCHI O.; NESTOR P.; ONDRUS M.; PAVESE N.; PERALTA M.C.; PICCINI P.; PINEDA-PARDO J.A.; REKTOROVÁ Irena; RODRÍGUEZ-OROZ M.
• Rok publikování: 2019
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
• Fakulta / Pracoviště MU: Středoevropský technologický institut
• www: https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.dadm.2019.01.011
• Doi: http://dx.doi.org/10.1016/j.dadm.2019.01.011
• Klíčová slova: Biomarker; CDB; CBS; MRI;MSA
• Popis: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.